526139 Stock Overview
A biotechnology company, provides research and development services for bulk drugs in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Transgene Biotek Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹5.27 |
| 52 Week High | ₹12.46 |
| 52 Week Low | ₹5.27 |
| Beta | 0.93 |
| 1 Month Change | -26.50% |
| 3 Month Change | -32.26% |
| 1 Year Change | -41.12% |
| 3 Year Change | 28.22% |
| 5 Year Change | 96.64% |
| Change since IPO | -96.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 526139 | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | -29.8% | 4.4% | 1.6% |
| 1Y | -41.1% | 30.3% | 17.5% |
Return vs Industry: 526139 underperformed the Indian Biotechs industry which returned 30.3% over the past year.
Return vs Market: 526139 underperformed the Indian Market which returned 17.5% over the past year.
Price Volatility
| 526139 volatility | |
|---|---|
| 526139 Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 526139's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 526139's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Koteswara Kanuru | www.transgenebiotek.com |
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers oncology drugs, oral drug delivery, and biogenerics, as well as HIV and multiple sclerosis drugs. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption.
Transgene Biotek Limited Fundamentals Summary
| 526139 fundamental statistics | |
|---|---|
| Market cap | ₹399.31m |
| Earnings (TTM) | -₹2.58m |
| Revenue (TTM) | ₹8.94m |
44.7x
P/S Ratio-154.7x
P/E RatioIs 526139 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 526139 income statement (TTM) | |
|---|---|
| Revenue | ₹8.94m |
| Cost of Revenue | ₹25.38k |
| Gross Profit | ₹8.91m |
| Other Expenses | ₹11.49m |
| Earnings | -₹2.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 99.72% |
| Net Profit Margin | -28.88% |
| Debt/Equity Ratio | 128.9% |
How did 526139 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/04 20:29 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Transgene Biotek Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|